FIELD: biotechnology.
SUBSTANCE: invention relates to therapeutic proteins fused with an Fc fragment, and can be used in medicine for the treatment of obesity, hyperlipidemia, non-alcoholic fatty liver disease, diabetes or diabetic cardiomyopathy. A combined therapeutic agent consisting of the first pharmaceutical composition containing the FGF21 Fc fusion protein and the second pharmaceutical composition containing the GLP-1 Fc fusion protein, and its use for the prevention or treatment of obesity, hyperlipidemia, non-alcoholic fatty liver disease, diabetes or diabetic cardiomyopathy are proposed.
EFFECT: achievement of a synergistic effect upon combined administration of the FGF21 Fc fusion protein and the GLP-1 Fc fusion protein in animal models of obesity, diabetes, hyperlipidemia, non-alcoholic fatty liver disease, diabetic cardiomyopathy.
7 cl, 9 dwg, 4 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
PROTEINS WITH A DOUBLE FUNCTION AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2016 |
|
RU2741345C2 |
NEW MODIFIED IMMUNOGLOBULIN Fc-FRAGMENT FUNCTION PROTEIN AND ITS USE | 2020 |
|
RU2800919C2 |
PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF HEPATITIS, LIVER FIBROSIS AND LIVER CIRRHOSIS, INCLUDING FUSION PROTEINS | 2017 |
|
RU2795548C2 |
FGF21 FUSED WITH LONG-ACTING PROTEINS AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 2016 |
|
RU2741087C2 |
IL-10/FC FUSION PROTEINS SUITABLE AS IMMUNOTHERAPY ENHANCERS | 2020 |
|
RU2825306C1 |
NOVEL PROTEIN CONJUGATE AND USE THEREOF FOR PREVENTING OR TREATING NON-ALCOHOLIC STEATOHEPATITIS, OBESITY AND DIABETES | 2021 |
|
RU2822001C1 |
HIGH GLYCATED FUSED PROTEIN BASED ON HUMAN BLOOD COAGULATION FACTOR VIII, METHOD FOR PRODUCTION THEREOF AND USE THEREOF | 2016 |
|
RU2722374C1 |
METHOD FOR OBTAINING BIFUNCTIONAL PROTEINS AND THEIR DERIVATIVES | 2018 |
|
RU2795970C2 |
TACI-Fc FUSION PROTEIN AND ITS USE | 2019 |
|
RU2814988C2 |
HUMAN COAGULATION FACTOR FUSED PROTEIN FX (FIX), METHOD FOR PRODUCTION AND USE THEREOF | 2017 |
|
RU2736339C1 |
Authors
Dates
2023-09-28—Published
2020-07-08—Filed